
Airway hyperresponsiveness: a complex interplay between airway inflammation, airway remodelling and structural changes<sup>1,2</sup>





IgE, immunoglobulin E; ILC2, type 2 innate lymphoid cell; Th, T helper

1. Comberiati P, et al. Immunol Allergy Clin North Am 2018;38:545–571; 2. Busse W. Chest 2010;138(Suppl. 2):45–10S; 3. Roan F, et al. J Clin Invest 2019;129:1441–1451; 4. Gunst SJ, Panettieri RA Jr. J Appl Physiol (1985) 2012;113:837–839; 5. Chapman DG, Irvin CG. Clin Exp Allergy 2015;45:706–719; 6. Gauvreau GM, et al. Expert Opin Ther Targets 2020;24:777–792; 7. Jeffery PK, et al. Am Rev Respir Dis 1989;140:1745–1753; 8. Boulet LP, et al. Chest 1997;112:45-52; 9. Booms P, et al. J Allergy Clin Immunol 1997;99:330-337; 10. Gelb AF, Zamel N. Curr Opin Pulm Med 2002;8:50-53; 11. Slats AM, et al. J Allergy Clin Immunol 2008;121:1196-1202; 12. Ward C, et al. Thorax 2002;57:309–316; 13. Brightling CE, et al. N Engl J Med 2002;346:1699–1705; 14. Bradding P, Arthur G. Clin Exp Allergy 2016;46:194–263; 15. Berair R, et al. J Allergy (Cairo) 2013;2013:185971; 16. Gil FR, Lauzon A-M. Can J Physiol Pharmacol 2007;85:133-140

Veeva ID: Z4-52232; date of preparation: February 2023. © 2023 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored and developed by AstraZeneca.




## Airway hyperresponsiveness: a complex interplay between airway inflammation, airway remodelling and structural changes<sup>1,2</sup>



#### Airway inflammation

- In response to external triggers, epithelial cytokines may initiate an inflammatory response<sup>1,3</sup>
- Inflammatory chemokines and cytokines, mast cell activation and airway smooth muscle cell proliferation contribute to the bronchoconstriction and airway hyperresponsiveness<sup>1–5</sup>
- Severity of airway hyperresponsiveness positively correlates with the number of eosinophils and mast cells in the airway<sup>5</sup>
- Airway hyperresponsiveness can occur independently of airway inflammation<sup>6</sup>

#### Variable contributions<sup>1,2</sup>



### Airway remodelling and structural changes

- Airway remodelling and structural changes are associated with airway hyperresponsiveness<sup>8–13</sup>
  - Infiltration of mast cells into airway smooth muscle and the resultant interactions between the two cell types are associated with disordered airway function and airway hyperresponsiveness<sup>14,15</sup>
  - Fundamental physiological changes in the airway smooth muscle, known as airway hypercontractility, involve mast cells and are hypothesised to be another cause of airway hyperresponsiveness<sup>16,17</sup>
- Airway remodelling and its contributions to airway hyperresponsiveness is an area of evolving research<sup>5,18,19</sup>

#### Persistent contributions<sup>1,2</sup>

Comberiati P, et al. Immunol Allergy Clin North Am 2018;38:545–571; 2. Busse W. Chest 2010;138(Suppl. 2):45–10S; 3. Roan F, et al. J Clin Invest 2019;129:1441–1451; 4. Gunst SJ, Panettieri RA Jr. J Appl Physiol (1985) 2012;113:837–839;
Chapman DG, Irvin CG. Clin Exp Allergy 2015;45:706–719; 6. Crimi E, et al. Am J Respir Crit Care Med 1998;157:4–9; 7. Gauvreau GM, et al. Expert Opin Ther Targets 2020;24:777–792; 8. Jeffery PK, et al. Am Rev Respir Dis 1989;140:1745–1753;
Boulet LP, et al. Chest 1997;112:45–52; 10. Booms P, et al. J Allergy Clin Immunol 1997;99:330–337; 11. Gelb AF, Zamel N. Curr Opin Pulm Med 2002;8:50–53; 12. Slats AM, et al. J Allergy Clin Immunol 2008;121:1196–1202;
Ward C, et al. Thorax 2002;57:309–316; 14. Brightling CE, et al. N Engl J Med 2002;346:1699–1705; 15. Bradding P, Arthur G. Clin Exp Allergy 2016;46:194–263; 16. Berair R, et al. J Allergy (Cairo) 2013;2013:185971;
Gil FR, Lauzon A-M. Can J Physiol Pharmacol 2007;85:133–140; 18. Fehrenbach H, et al. Cell Tissue Res 2017;367:551–569; 19. Hough KP, et al. Front Med (Lausanne) 2020;7:191


Veeva ID: Z4-52232; date of preparation: February 2023. © 2023 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored and developed by AstraZeneca.



# Multiple factors contribute to airway hyperresponsiveness: airway inflammation



The degree and/or severity of airway inflammation contributes to the variability of airway hyperresponsiveness in patients<sup>1,2</sup>



Triggers include allergens,<sup>3,4</sup> infections,<sup>5,6</sup> occupational triggers (TDI)<sup>7,8</sup> and environmental triggers ( $O_3$ ,  $NO_2$ , diesel exhaust)<sup>9</sup>

Epithelial cytokines, including TSLP, IL-25 and IL-33, are released from epithelial cells and induce the release of downstream inflammatory cytokines (eg IL-4, IL-5 and IL-13) that may drive inflammation, bronchoconstriction and airway hyperresponsiveness<sup>1,10,11</sup>

Intraepithelial mast cells and eosinophils are also associated with indirect and endogenous airway hyperresponsiveness, respectively, with eosinophils also being associated with T2 inflammation<sup>12–14</sup>

Severity of airway hyperresponsiveness positively correlates with the number of eosinophils and mast cells in the airways<sup>15</sup>

#### However, airway hyperresponsiveness can occur independently of airway inflammation<sup>16</sup>

IL, interleukin; NO<sub>2</sub>, nitrogen dioxide; O<sub>3</sub>, ozone; T2, type 2; TDI, toluene diisocyanate; TSLP, thymic stromal lymphopoietin

Comberiati P, et al. Immunol Allergy Clin North Am 2018;38:545–571; 2. Busse W. Chest 2010;138(Suppl. 2):4S–10S; 3. Metzger WJ, et al. Chest 1986;89:477–483; 4. Cartier A, et al. J Allergy Clin Immunol 1982;70:170–177;
Empey DW, et al. Am Rev Respir Dis 1976;113:131–139; 6. Laitinen LA, et al. Am Rev Respir Dis 1991;143:358–361; 7. Mapp C, et al. Am Rev Respir Dis 1987;136:1403–1407; 8. Fabbri LM, et al. Am Rev Respir Dis 1987;136:36–42;
Olivieri D, Scoditti E. Eur Respir Rev 2005;14:51–56; 10. Gunst SJ, Pannettieri RA Jr. J Appl Physiol (1985) 2012;113:837–839; 11. Roan F, et al. J Clin Invest 2019;129:1441–1451; 12. Lai Y, et al. J Allergy Clin Immunol 2014;133:1448–1455;
Altman MC, et al. J Clin Invest 2019;129:4979–4991; 14. Al-Shaikhly T, et al. Eur Respir J 2022;60:2101865; 15. Chapman DG, Irvin CG. Clin Exp Allergy 2015;45:706–719; 16. Crimi E, et al. Am J Respir Crit Care Med 1998;157:4–9




### Multiple factors contribute to airway hyperresponsiveness: airway remodelling and structural changes



- Airway remodelling, encompassing a range of structural changes, is considered to have permanent/persistent contributions to airway hyperresponsiveness<sup>1,2</sup>
- Infiltration of mast cells into airway smooth muscle and the resultant interactions between the two cell types are associated with disordered airway function and airway hyperresponsiveness<sup>3,4</sup>
- Fundamental physiological changes in the airway smooth muscle, known as airway hypercontractility, involve mast cells and are hypothesised to be another cause of airway hyperresponsiveness<sup>5,6</sup>
- Airway remodelling/structural changes and their contributions to airway hyperresponsiveness is an area of evolving research<sup>7–9</sup>

Structural changes responsible for the bronchoconstriction observed in airway hyperresponsiveness include:



Comberiati P, et al. Immunol Allergy Clin North Am 2018;38:545–571; 2. Busse W. Chest 2010;138(Suppl. 2):45–10S; 3. Brightling CE, et al. N Engl J Med 2002;346:1699–1705;
Bradding P, Arthur G. Clin Exp Allergy 2016;46:194–263; 5. Berair R, et al. J Allergy (Cairo) 2013;2013:185971; 6. Gil FR, Lauzon A-M. Can J Physiol Pharmacol 2007;85:133–140; 7. Chapman DG, Irvin CG. Clin Exp Allergy 2015;45:706–719;
Fehrenbach H, et al. Cell Tissue Res 2017;367:551–569; 9. Hough KP, et al. Front Med (Lausanne) 2020;7:191; 10. Jeffery PK, et al. Am Rev Respir Dis 1989;140:1745–1753; 11. Heijink IH, et al. Allergy 2020;75:1902–1917;
Mauad T, et al. Am J Respir Crit Care Med 2004;170:857–862; 13. Booms P, et al. J Allergy Clin Immunol 1997;99:330–337; 14. Ward C, et al. Thorax 2002;57:309–316; 15. Gelb AF, Zamel N. Curr Opin Pulm Med 2002;8:50–53;
James AL, et al. Am J Respir Crit Care Med 2012;185:1058–1064; 17. Slats AM, et al. J Allergy Clin Immunol 2008;121:1196–1202; 18. Boulet LP, et al. Chest 1997;112:45–52



Veeva ID: Z4-52232; date of preparation: February 2023. © 2023 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored and developed by AstraZeneca.